Megan Fitzgerald

University of Wisconsin Carbone Cancer Center

Papers

Total Citations

H-Index

About

Megan Fitzgerald is a leading researcher in drug metabolism and toxicology, with a primary focus on UDP-glucuronosyltransferase (UGT) enzymes and their role in drug development. Her most cited work, "High Throughput Screening Assay for UDP-Glucuronosyltransferase 1A1 Glucuronidation Profiling" (2007, 22 citations), introduced a groundbreaking high-throughput screening (HTS) assay for UGT1A1 glucuronidation. This assay enables rapid evaluation of compound toxicity and potential drug-drug interactions, a critical step in producing safer drug candidates and reducing development costs. Fitzgerald’s contributions have advanced the field by providing a practical tool for early-stage drug metabolism profiling, helping to identify problematic compounds before costly clinical trials. Her work is particularly notable for its impact on improving the efficiency and safety of the drug development pipeline. With her innovative approach to HTS assays, Fitzgerald has established herself as a key figure in pharmaceutical toxicology, and her research continues to guide the design of better drug candidates. Her achievements underscore the importance of integrating metabolic profiling into early drug discovery.